Bone Loss in Women With Anorexia Nervosa
Primary Purpose
Anorexia Nervosa
Status
Completed
Phase
Phase 2
Locations
United States
Study Type
Interventional
Intervention
Testosterone
Actonel (risedronate)
Placebo Actonel (risedronate)
Placebo testosterone
Sponsored by
About this trial
This is an interventional treatment trial for Anorexia Nervosa focused on measuring Eating Disorders, Osteopenia
Eligibility Criteria
Inclusion Criteria: Anorexia Nervosa, Over 18, Female, Decreased bone density Exclusion Criteria: Medications to increase bone density
Sites / Locations
- Massachusetts General Hospital
Arms of the Study
Arm 1
Arm 2
Arm 3
Arm 4
Arm Type
Active Comparator
Active Comparator
Active Comparator
Placebo Comparator
Arm Label
2
3
4
1
Arm Description
Placebo Actonel (risedronate) and active testosterone patch
Active Actonel (risedronate) and active testosterone patch
Active Actonel (risedronate) and placebo testosterone
Placebo testosterone patch and placebo Actonel (risedronate)
Outcomes
Primary Outcome Measures
Bone Mineral Density
Percent change in postero-anterior (PA) spine bone mineral density as measured by dual energy x-ray absorptiometry (DXA)over a 12-month period. The differences in log-transformed values are reported as percent change.
Secondary Outcome Measures
Markers of Bone Metabolism
type 1 collagen C-telopeptide(CTX); The differences in log-transformed values are reported as percent change.
Full Information
NCT ID
NCT00089843
First Posted
August 16, 2004
Last Updated
August 31, 2020
Sponsor
Massachusetts General Hospital
Collaborators
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Center for Research Resources (NCRR)
1. Study Identification
Unique Protocol Identification Number
NCT00089843
Brief Title
Bone Loss in Women With Anorexia Nervosa
Official Title
IGF-1 and Bone Loss in Women Anorexia Nervosa
Study Type
Interventional
2. Study Status
Record Verification Date
August 2020
Overall Recruitment Status
Completed
Study Start Date
June 2003 (undefined)
Primary Completion Date
April 2008 (Actual)
Study Completion Date
April 2008 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Massachusetts General Hospital
Collaborators
National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), National Center for Research Resources (NCRR)
4. Oversight
Data Monitoring Committee
Yes
5. Study Description
Brief Summary
Women with Anorexia Nervosa have been found to have low bone density. The study will determine whether administration of low doses of a natural hormone, testosterone and/or risedronate, a medication to help prevent bone breakdown will improve or prevent bone loss in this condition.
Detailed Description
II. SPECIFIC AIMS
Severe osteopenia is a prevalent complication of anorexia nervosa (AN), affecting over half of all women with this disease. Loss of 25-50% of total bone mass occurs frequently and is often permanent. Although anorexia nervosa affects from 0.5-1.0% of college age women, no successful therapeutic interventions have been developed for osteoporosis in this population. Bone loss in anorexia nervosa is characterized by reduced bone formation coupled with increased bone resorption. Anorexia nervosa results in a deficiency of testosterone. Testosterone administration reduces bone resorption and data suggest that low-dose testosterone replacement therapy can increase surrogate markers of bone formation. Bisphosphonates are now well established to decrease bone resorption and improve bone density in severely osteopenic postmenopausal women. However, there are few data regarding the use of this antiresorptive therapy in women with severe pre-menopausal bone loss. Our preliminary data demonstrate that administration of a bisphosphonate decreases bone resorption and increases bone mass in women with AN after 6 and 9 months. These are the first data to demonstrate a striking increase in bone density in such women. We will test the hypothesis that a combined strategy to increase bone formation and decrease bone resorption by combining testosterone with a bisphosphonate will increase bone mass in anorexia nervosa.
The following hypotheses will be tested:
Specific Aim 1. Testosterone, a nutritionally dependent bone trophic factor, is a critical determinant of decreased bone formation in anorexia nervosa, and administration of physiologic testosterone will increase bone formation and lean body mass in this disease
We will investigate in women with anorexia nervosa whether:
A. Bone formation is reduced in association with low serum testosterone B. Testosterone deficiency is due to a combination of ovarian and adrenal defects resulting from undernutrition C. Testosterone administration reverses testosterone deficiency leading to an acute and sustained increase in bone formation and a decrease in bone resorption D. Administration of physiologic testosterone replacement stimulates increases in IGF-I levels in women with anorexia nervosa, a mechanism for increased bone formation and bone density E. Administration of physiologic testosterone replacement increases lean body mass, a major determinant of bone density
Specific Aim 2. Long-term (12 months) physiologic testosterone administration combined with a bisphosphonate increases bone density by a dual anabolic and anti-resorptive strategy
We will investigate in women with anorexia nervosa whether:
A. Physiologic testosterone administration increases bone density B. Administration of a bisphosphonate decreases the excessive state of bone resorption and increases bone density C. Co-administration of physiologic testosterone replacement and a bisphosphonate increases bone density to a greater degree than testosterone or a bisphosphonate alone by increasing bone formation and decreasing bone resorption
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Anorexia Nervosa
Keywords
Eating Disorders, Osteopenia
7. Study Design
Primary Purpose
Treatment
Study Phase
Phase 2, Phase 3
Interventional Study Model
Factorial Assignment
Masking
ParticipantCare ProviderInvestigatorOutcomes Assessor
Allocation
Randomized
Enrollment
77 (Actual)
8. Arms, Groups, and Interventions
Arm Title
2
Arm Type
Active Comparator
Arm Description
Placebo Actonel (risedronate) and active testosterone patch
Arm Title
3
Arm Type
Active Comparator
Arm Description
Active Actonel (risedronate) and active testosterone patch
Arm Title
4
Arm Type
Active Comparator
Arm Description
Active Actonel (risedronate) and placebo testosterone
Arm Title
1
Arm Type
Placebo Comparator
Arm Description
Placebo testosterone patch and placebo Actonel (risedronate)
Intervention Type
Drug
Intervention Name(s)
Testosterone
Other Intervention Name(s)
Intrinsa
Intervention Description
Testosterone patch 150mcg daily
Intervention Type
Drug
Intervention Name(s)
Actonel (risedronate)
Other Intervention Name(s)
Actonel
Intervention Description
Actonel (risedronate) 35mg PO one time weekly
Intervention Type
Drug
Intervention Name(s)
Placebo Actonel (risedronate)
Intervention Description
Placebo tablet identical in appearance to active Actonel (risedronate) tablet
Intervention Type
Drug
Intervention Name(s)
Placebo testosterone
Intervention Description
Placebo patch identical in appearance to testosterone patch
Primary Outcome Measure Information:
Title
Bone Mineral Density
Description
Percent change in postero-anterior (PA) spine bone mineral density as measured by dual energy x-ray absorptiometry (DXA)over a 12-month period. The differences in log-transformed values are reported as percent change.
Time Frame
Baseline and 12 months
Secondary Outcome Measure Information:
Title
Markers of Bone Metabolism
Description
type 1 collagen C-telopeptide(CTX); The differences in log-transformed values are reported as percent change.
Time Frame
Baseline to 12 months
10. Eligibility
Sex
Female
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
45 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Anorexia Nervosa,
Over 18,
Female,
Decreased bone density
Exclusion Criteria:
Medications to increase bone density
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Anne Klibanski, M.D.
Organizational Affiliation
Massachusetts General Hospital
Official's Role
Principal Investigator
Facility Information:
Facility Name
Massachusetts General Hospital
City
Boston
State/Province
Massachusetts
ZIP/Postal Code
02114
Country
United States
12. IPD Sharing Statement
Citations:
PubMed Identifier
17592924
Citation
Miller KK, Wexler TL, Zha AM, Lawson EA, Meenaghan EM, Misra M, Binstock AB, Herzog DB, Klibanski A. Androgen deficiency: association with increased anxiety and depression symptom severity in anorexia nervosa. J Clin Psychiatry. 2007 Jun;68(6):959-65. doi: 10.4088/jcp.v68n0621.
Results Reference
derived
Learn more about this trial
Bone Loss in Women With Anorexia Nervosa
We'll reach out to this number within 24 hrs